Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2′-deoxycytidine

被引:0
作者
Wei Hua YAN
Ai Fen LIN
Chien Chung CHANG
Soldano FERRONE
机构
[1] Laboratory Center,Department of Immunology
[2] Wenzhou Medical College Affiliated Taizhou Hospital,undefined
[3] Roswell Park Cancer Institute,undefined
来源
Cell Research | 2005年 / 15卷
关键词
HLA-G; methylation; 5-aza-2′-deoxycytidine; APM;
D O I
暂无
中图分类号
学科分类号
摘要
The non-classical HLA class I antigen HLA-G is an immune modulator which inhibits the functions of T cells, NK cells, and the Dendritic cells (DC). As a result, HLA-G expression in malignant cells may provide them with a mechanism to escape the immune surveillance. In melanoma, HLA-G antigen expression has been found in 30% of surgically removed lesions but in less than 1% of established cell lines. One possible mechanism underlying the differential HLA-G expression in vivo and in vitro is that the HLA-G gene is epigenetically repressed in melanoma cells in vitro. To test this hypothesis, we treated the HLA-G negative melanoma cell line OCM-1A with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-AC) and analyzed whether HLA-G expression can be restored. Our data strongly suggest that HLA-G is silenced as a result of CpG hypermethylation within a 5' regulatory region encompassing 220 bp upstream of the start codon. After treatment, HLA-G mRNA expression was dramatically increased. Western blot and flow cytometry showed that HLA-G protein was induced. Interestingly, HLA-G cell surface expression on the 5-AC treated OCM-1A cells is much less than that on the HLA-G positive JEG-3 cells while a similar amount of total HLA-G was observed. Possible mechanisms for the difference were analyzed in the study such as cell cold-treatment, peptide loading and antigen processing machinery components (APM) as well as β2 microglobulin (β2-m) expression. Data revealed that the APM component calreticulin might be involved in the lower HLA-G surface expression on OCM-1A cells. Taken together, our results indicated that DNA methylation is an important epigenetic mechanism by which HLA-G antigen expression is modulated in melanoma cells in vitro. Furthermore, to the first time, we hypothesized that the deficiency of calreticulin might be involved in the low HLA-G surface expression on the 5-AC treated OCM-1A cells.
引用
收藏
页码:523 / 531
页数:8
相关论文
共 97 条
  • [1] Carosella ED(2001)HLA-G: a shield against inflammatory aggression Trends Immunol 22 553-5
  • [2] Moreau P(2002)HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy Eur J Immunol 32 311-5
  • [3] Aracting S(1998)HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance Proc Natl Acad Sci U S A 95 4510-5
  • [4] Rouas-Freiss N(2001)Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production Am J Pathol 159 817-24
  • [5] Fuzzi B(2001)Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma Cancer Res 61 6838-45
  • [6] Rizzo R(2005)Residues Met Cell Res 15 176-82
  • [7] Criscuoli L(2003) and Gln Semin Cancer Biol 13 317-23
  • [8] Paul P(2005) in HLA-G α1 domain involved in KIR2DL4 recognition Int J Cancer 113 928-36
  • [9] Rouas-Freiss N(2003)HLA-G modulates immune responses by diverse receptor interactions Clin Cancer Res 9 4460-4
  • [10] Khalil-Daher I(2005)HLA-G gene activation in tumor cells involves cis-acting epigenetic changes Gynecol Oncol 96 42-7